Liminal BioSciences — Investor Presentation (May 2022)
22 slides from Liminal BioSciences's investor presentation, May 24, 2022
Slide 1: Corporate Presentation
Aiming to develop Best/First-In-Class Novel Small Molecule Therapeutics for Inflammatory, Metabolic and Fibrotic Diseases Corporate Presentation NASDAQ: LMNL May 2022
Slide 2: Safe Harbour
Safe Harbour This presentation contains forward-looking statements about Liminal BioSciences’ objectives, strategies and businesses that involve risks and uncertainties. Forward‐looking information includes statements concerning, among other things, advancement of Liminal Biosciences’ product candid
Slide 3: Liminal Introduction
Aiming to develop Best/First In Class Novel Small Molecule Therapeutics for Inflammatory, Metabolic and Fibrotic Diseases Liminal Introduction Pipeline is positioned to deliver multiple value inflection milestones in 2022/23 Intellectual Property (IP) all under the control of Liminal Progressing Div
Slide 4: Experienced management team
LMNL is led by a strong, experienced team with proven track records in the discovery, development, and approval of biopharmaceuticals, all driven to make a difference. Management Team Bruce Pritchard Chief Executive Officer Executive Finance Positions: Prometic Life Sciences Inc., CV Therapeutics In
Slide 5: Focus on compelling biological mechanisms and value creation
At Liminal, we are focused on elucidating compelling biological mechanisms and plan to advance a pipeline of small molecule therapeutics with best/first-in-class potential across a broad range of significant commercial opportunities. Compelling Biological Mechanisms Data-Driven. Dedicated. We focus
Slide 6: Pipeline overview: fezagepras, GPR84, OXER1
The conjugation of fezagepras with glutamine shows that fezagepras has the potential to act as a “nitrogen scavenging” drug. Nitrogen scavenger drugs are used in the treatment of conditions characterized by hyperammonaemia such as Urea Cycle Disorders and Hepatic Encephalopathy. Fezagepras The GPR84
Slide 7: Pipeline status and expected milestones
Completed a Multiple Ascending Dose (MAD) clinical trial which provided support for the hypothesis that fezagepras has nitrogen scavenging properties. First subject dosed in Phase 1a Single Ascending Dose (SAD) clinical trial designed as a head-to-head comparison with Sodium Phenylbutyrate in May 20
Slide 8: Our Lead Candidate: Fezagepras
Our Lead Candidate: Fezagepras
Slide 9: Fezagepras clinical history and nitrogen scavenging
In December 2020 the Company initiated a Phase 1 Multiple Ascending Dose (MAD) trial in Fezagepras with a view to proceed with a Phase 2 clinical trial in fibrosis. By mid-2021, based on preliminary PK data from the Phase 1 MAD clinical trial, the Company announced its plan to discontinue the develo
Slide 10: Fezagepras: Near-term Clinical Development Plan
Fezagepras: Near-term Clinical Development Plan * Follow on clinical trials subject to result of Phase 1a SAD and relevant regulatory approvals Established baseline safety & PK profile Completed Phase 1 MAD Phase 1a SAD Phase 1a MAD Phase 1b SMAD Timing Study Goal Early Biomarker Data Dose Selection
Slide 11: Our Early-Stage Candidates
Our Early-Stage Candidates
Slide 12: GPR84 antagonist
GPR84 antagonist
Slide 13: GPR84: Role in Inflammation and Fibrosis
GPR84: Role in Inflammation and Fibrosis = GPR84 = agonist Neutrophil Monocyte/Macrophage ROS = Reactive oxygen species Pro-inflammatory/ Pro-fibrotic Activity GPR84 Agonists Pro-inflammatory cytokines Oxidative burst / ROS Chemotaxis Inflammatory conditions increase GPR84 expression
Slide 14: GPR84 Receptor
GPR84 Receptor Primarily expressed in immune cells Plays a key role in the linkage and regulation of the inflammatory and metabolic response Promotes fibrosis Antagonism of the GPR84 receptor proposes a potentially novel therapy for disease processes characterized by immunometabolism dysfunction suc
Slide 15: Next steps for GPR84
Next steps for GPR84 Commence enabling studies for regulatory approval of clinical trial File for regulatory approval for clinical trial 2023 Commence first-in-human clinical trial 2022 Preclinical candidate selection
Slide 16: OXER1 Antagonist
OXER1 Antagonist
Slide 17: OXER1: Role in Tissue Repair and Inflammation
OXER1: Role in Tissue Repair and Inflammation OXER1 is a GPCR receptor which is mainly expressed in inflammatory cells Predominantly in eosinophils where the relative expression when compared to neutrophils and macrophages is 200:6:1 respectively. OXER1 is specific for the ligand 5-oxo-ETE which
Slide 18: Eosinophils: Both Effector and Immune-Regulator Cells
Eosinophils: Both Effector and Immune-Regulator Cells Eosinophils are major effector cells in the immune system Part of the innate immune system; traditionally recognised as the first line of defence against parasitic infections When activated, they release a cocktail of toxic proteins along with cy
Slide 19: Eosinophils in Disease
Eosinophils in Disease Gastrointestinal Diseases Respiratory Diseases Other Diseases Skin Diseases Eosinophils are involved in acute and chronic inflammation and play an important role in a large number of allergic, inflammatory and proliferative diseases. Both eosinophils and mast cells are involve
Slide 20: Development Rationale & Opportunities in Eosinophil-related Diseases
Development Rationale & Opportunities in Eosinophil-related Diseases Eosinophil-targeting biology proven with existing, approved, monoclonal antibody drugs Reducing eosinophil levels shown to improve outcomes in severe asthma Blood eosinophil levels offer an easy-to-measure biomarker for early-stage
Slide 21: Expected Milestones
Expected Milestones Fezagepras Q2 2022: Phase 1a SAD Clinical trial H2 2022: Update on the outcome of this additional research and provide update on determining any potential new target diseases H2 2022: Market update on any further development plans for fezagepras GPR84 2022: Pre-clinical Candidate
Slide 22: Financed to Deliver on Expected Milestones
All figures presented in this section are in Canadian dollars unless otherwise specified. Financed to Deliver on Expected Milestones Cash as of March 31, 2022 $61.2M Cash Runway sufficient to support program-related milestones described on slide 21 Ongoing opportunity to monetise non-core assets Acc
Liminal BioSciences — Investor Presentation (May 2022) on 6ix